Cargando…
Loss of treatment benefit due to low compliance with bisphosphonate therapy
SUMMARY: Among 8,822 new female bisphosphonate users, non-compliant bisphosphonate use was associated with a 45% increased risk of osteoporotic fracture compared to compliant use (MPR ≥80%). Classifying compliance into five categories, fracture risk gradually increased with poorer compliance. These...
Autores principales: | Penning-van Beest, F. J. A., Erkens, J. A., Olson, M., Herings, R. M. C. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267483/ https://www.ncbi.nlm.nih.gov/pubmed/17874028 http://dx.doi.org/10.1007/s00198-007-0466-1 |
Ejemplares similares
-
Which Bisphosphonate? It's the Compliance!: Decision Analysis
por: Lee, You Jin, et al.
Publicado: (2016) -
Existing Data Sources for Clinical Epidemiology: The PHARMO Database Network
por: Kuiper, Josephina G, et al.
Publicado: (2020) -
Risks and benefits of bisphosphonates
por: Coleman, R E
Publicado: (2008) -
Oral bisphosphonate compliance and persistence: a matter of choice?
por: Silverman, S. L., et al.
Publicado: (2010) -
Completeness and Representativeness of the PHARMO General Practitioner (GP) Data: A Comparison with National Statistics
por: Overbeek, Jetty A, et al.
Publicado: (2023)